Bicyclic Imidazoles as a Novel Class of Cytokine Biosynthesis Inhibitors

[1]  Jiahuai Han,et al.  Endotoxin-responsive sequences control cachectin/tumor necrosis factor biosynthesis at the translational level [published erratum appears in J Exp Med 1990 Mar 1;171(3):971-2] , 1990, The Journal of experimental medicine.

[2]  T. Yokota,et al.  Cytokines: coordinators of immune and inflammatory responses. , 1990, Annual review of biochemistry.

[3]  P. Janssen,et al.  Novel broad-spectrum anthelmintics. Tetramisole and related derivatives of 6-arylimidazo[2,1-b]thiazole. , 1966, Journal of medicinal chemistry.

[4]  S. Endres,et al.  The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-alpha production by human mononuclear cells. , 1993, International journal of immunopharmacology.

[5]  V. Danis,et al.  The effect of gold sodium thiomalate and auranofin on lipopolysaccharide‐induced interleukin‐1 production by blood monocytes in vitro: variation in healthy subjects and patients with arthritis , 1990, Clinical and experimental immunology.

[6]  J. Lombardino,et al.  Preparation and antiinflammatory activity of some nonacidic trisubstituted imidazoles. , 1974, Journal of medicinal chemistry.

[7]  M. Kozak.  The scanning model for translation: an update , 1989, The Journal of cell biology.

[8]  D. Remick,et al.  Oxygen radical scavengers selectively inhibit interleukin 8 production in human whole blood. , 1992, The Journal of clinical investigation.

[9]  R. Jackson,et al.  Inhibition by probucol of interleukin 1 secretion and its implication in atherosclerosis. , 1988, The American journal of cardiology.

[10]  Yan Zhang,et al.  Neutrophil recruitment by tumor necrosis factor from mast cells in immune complex peritonitis. , 1992, Science.

[11]  G. Mundy,et al.  Actions of recombinant interleukin 1, interleukin 2, and interferon-gamma on bone resorption in vitro. , 1986, Journal of immunology.

[12]  C. Choi,et al.  Cytokine release from microglia: differential inhibition by pentoxifylline and dexamethasone. , 1992, The Journal of infectious diseases.

[13]  K. O. Elliston,et al.  A novel heterodimeric cysteine protease is required for interleukin-1βprocessing in monocytes , 1992, Nature.

[14]  B. Beutler,et al.  Identification of a common nucleotide sequence in the 3'-untranslated region of mRNA molecules specifying inflammatory mediators. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[15]  C. Hannum,et al.  An IL-1 inhibitor from human monocytes. Production and characterization of biologic properties. , 1989, Journal of immunology.

[16]  John C. Lee,et al.  Chapter 20 Pharmacological Modulation of Interleukin-1 , 1990 .

[17]  A. Ferrante,et al.  Tetrandrine, a plant alkaloid, inhibits the production of tumour necrosis factor‐alpha (cachectin) hy human monocytes , 1990, Clinical and experimental immunology.

[18]  P. Bender,et al.  Antiinflammatory activity of 5,6-diaryl-2,3-dihydroimidazo[2,1-b]thiazoles. Isomeric 4-pyridyl and 4-substituted phenyl derivatives. , 1984, Journal of medicinal chemistry.

[19]  I. Otterness,et al.  Inhibition of interleukin 1 synthesis by tenidap: a new drug for arthritis. , 1991, Cytokine.

[20]  N. Yuhki,et al.  Neutrophil attractant/activation protein-1 and monocyte chemoattractant protein-1 in rabbit. cDNA cloning and their expression in spleen cells. , 1991, Journal of immunology.

[21]  M. Gowen,et al.  Cytokines and bone. , 1992, British journal of rheumatology.

[22]  J. Lee,et al.  Beneficial effects of SK&F 105809, a novel cytokine-suppressive agent, in murine models of endotoxin shock. , 1992, Circulatory shock.

[23]  S. Dower,et al.  Regulation of alloreactivity in vivo by a soluble form of the interleukin-1 receptor. , 1990, Science.

[24]  P. Schur,et al.  The effect of antirheumatic drugs on interleukin 1 (IL-1) activity and IL-1 and IL-1 inhibitor production by human monocytes. , 1990, The Journal of rheumatology.

[25]  Jilly F. Evans,et al.  Identification and isolation of a membrane protein necessary for leukotriene production , 1990, Nature.

[26]  E. Puscheck,et al.  Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[27]  C. Dinarello,et al.  The influence of lipoxygenase inhibitors on the in vitro production of human leukocytic pyrogen and lymphocyte activating factor (interleukin-1). , 1984, International journal of immunopharmacology.

[28]  G. Mundy,et al.  Tumor necrosis factors alpha and beta induce osteoblastic cells to stimulate osteoclastic bone resorption. , 1987, Journal of immunology.

[29]  S. Teitelbaum,et al.  Spontaneous release of interleukin 1 from human blood monocytes reflects bone formation in idiopathic osteoporosis. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[30]  L. Bonewald,et al.  Infusions of recombinant human interleukins 1 alpha and 1 beta cause hypercalcemia in normal mice. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[31]  H. Sarau,et al.  SK&F 86002: a structurally novel anti-inflammatory agent that inhibits lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid. , 1987, Biochemical pharmacology.

[32]  S. Schreiber,et al.  A receptor for the immuno-suppressant FK506 is a cis–trans peptidyl-prolyl isomerase , 1989, Nature.

[33]  L. Avioli,et al.  Ovarian steroid treatment blocks a postmenopausal increase in blood monocyte interleukin 1 release. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J. Lee,et al.  Pharmacology of the pyrroloimidazole, SK&F 105809--II. Antiinflammatory activity and inhibition of mediator production in vivo. , 1991, Biochemical pharmacology.

[35]  W. Reutter,et al.  Galactosamine-induced sensitization to the lethal effects of endotoxin. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[36]  C. Dinarello.  Interleukin-1 and interleukin-1 antagonism. , 1991, Blood.

[37]  B. Barton,et al.  Cytokine inhibition by a novel steroid, mometasone furoate. , 1991, Immunopharmacology and immunotoxicology.

[38]  T. Bringman,et al.  Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors , 1986, Nature.

[39]  H. Towbin,et al.  An assay for the detection of interleukin-1 synthesis inhibitors: effects of antirheumatic drugs. , 1989, Drugs under experimental and clinical research.

[40]  A. Rot.  Endothelial cell binding of NAP-1/IL-8: role in neutrophil emigration. , 1992, Immunology today.

[41]  J. Talmadge,et al.  Protective effect of SK&F 86002, a novel dual inhibitor of arachidonic acid metabolism, in murine models of endotoxin shock: inhibition of tumor necrosis factor as a possible mechanism of action. , 1989, Circulatory shock.

[42]  G. Shaw,et al.  A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation , 1986, Cell.

[43]  J. Walters,et al.  Stimulation of interleukin-1 alpha and interleukin-1 beta production in human monocytes by protein phosphatase 1 and 2A inhibitors. , 1993, The Journal of biological chemistry.

[44]  C. Chenu,et al.  Interleukin‐1 and tumor necrosis factor stimulate the formation of human osteoclastlike cells in vitro , 1989, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[45]  H. Sarau,et al.  Pharmacology of the pyrroloimidazole, SK&F 105809--I. Inhibition of inflammatory cytokine production and of 5-lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid. , 1991, Biochemical pharmacology.

[46]  D. Kioussis,et al.  Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. , 1991, The EMBO journal.

[47]  R. Strieter,et al.  Endothelial cell gene expression of a neutrophil chemotactic factor by TNF-alpha, LPS, and IL-1 beta. , 1989, Science.

[48]  C V Jongeneel,et al.  Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor alpha gene in primary macrophages , 1990, The Journal of experimental medicine.

[49]  Y. Mizushima,et al.  Immunological and anti-inflammatory effects of clarithromycin: inhibition of interleukin 1 production of murine peritoneal macrophages. , 1989, Drugs under experimental and clinical research.

[50]  H. Masamune,et al.  Chapter 22. Cytokine Modulation as a Medicinal Chemistry Target , 1992 .

[51]  C G Figdor,et al.  Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes , 1991, The Journal of experimental medicine.

[52]  N. Hanna,et al.  Effect of inhibitors of eicosanoid metabolism in murine collagen-induced arthritis. , 1988, Arthritis and rheumatism.

[53]  I. Colditz,et al.  The effect of cytokines and chemotactic agonists on the migration of T lymphocytes into skin. , 1992, Immunology.

[54]  J. Lee,et al.  Inhibition of monocyte IL-1 production by the anti-inflammatory compound, SK&F 86002. , 1988, International journal of immunopharmacology.

[55]  S. Sung,et al.  Stimulation of tumor necrosis factor alpha production in human monocytes by inhibitors of protein phosphatase 1 and 2A , 1992, The Journal of experimental medicine.

[56]  Glucocorticoids selectively inhibit the transcription of the interleukin 1 beta gene and decrease the stability of interleukin 1 beta mRNA. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[57]  G. Shaw,et al.  Translational blockade imposed by cytokine-derived UA-rich sequences. , 1989, Science.

[58]  B. Beutler,et al.  A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity , 1991, The Journal of experimental medicine.

[59]  J. Dayer,et al.  Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. , 1990, Arthritis and rheumatism.

[60]  L. Raisz.  BONE RESORPTION IN TISSUE CULTURE. FACTORS INFLUENCING THE RESPONSE TO PARATHYROID HORMONE. , 1965, The Journal of clinical investigation.

[61]  A. Tashjian,et al.  Tumor necrosis factor-alpha (cachectin) stimulates bone resorption in mouse calvaria via a prostaglandin-mediated mechanism. , 1987, Endocrinology.

[62]  John C. Lee,et al.  Inhibition of human monocyte IL-1 production by SK&F 86002 , 1990 .

[63]  B. Beutler,et al.  Translational control mediated by UA-rich sequences. , 1990, Enzyme.

[64]  Eric O Long,et al.  Class II MHC molecules and the HIV gp 120 envelope protein interact with functionally distinct regions of the CD4 molecule. , 1989, The EMBO journal.